Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease
Authors' conclusion
TSI and TRAb are strongly correlated in GD, with slow antibody decline linked to unresolved hyperthyroidism. Discontinuing ATDs may be considered when both TSI and TRAb are negative.
Study context
- Population
- Patients newly diagnosed with Graves disease (GD)762 female, 195 male
- Participants
- 957 patients
- Exposure
- Unresolved (Group A) vs resolved (Group B) hyperthyroidism after 1 month of therapy; Thyroid-stimulating immunoglobulin (TSI) and thyrotropin receptor antibody (TRAb) correlation
- Outcome
- Correlation between TRAb and TSI
Methodological detailsretrospective data analysis
- Retrospective data analysis
Main finding
As reported in the abstract
Strong correlation between TRAb and TSI (r)
r = 0.873
P < .001
Observational data: associations, not effects.
Further findings
Relapse after ATD discontinuation · follow-up over 12 months after ATD discontinuation
- Relapse rate (206 patients followed)
- 41.26%
- Relapse more frequent with positive TSI (54.84% vs 35.42%)
- P < 0.05
- Independent relapse predictors: positive TSI at withdrawal, past history of GD, age, mild thyroid-associated ophthalmopathy
Original publication
Significance of Thyroid-Stimulating Immunoglobulin and Thyrotropin Receptor Antibody in Graves Disease. J Clin Endocrinol Metab. Published 23 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →